US 8598333
SiRNA silencing of genes expressed in cancer
granted A61KA61K31/575A61K31/7088
Quick answer
US patent 8598333 (SiRNA silencing of genes expressed in cancer) held by Alnylam Pharmaceuticals, Inc. expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Dec 03 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61K, A61K31/575, A61K31/7088